Last reviewed · How we verify
Alprazolam + Aerobic exercise
Alprazolam reduces anxiety and panic by enhancing GABAergic inhibition in the central nervous system, while aerobic exercise improves mood and anxiety symptoms through neurobiological adaptations including increased endorphin release and improved cardiovascular function.
Alprazolam reduces anxiety and panic by enhancing GABAergic inhibition in the central nervous system, while aerobic exercise improves mood and anxiety symptoms through neurobiological adaptations including increased endorphin release and improved cardiovascular function. Used for Anxiety disorders with panic attacks, Generalized anxiety disorder (GAD).
At a glance
| Generic name | Alprazolam + Aerobic exercise |
|---|---|
| Also known as | Exercise group |
| Sponsor | University of Buenos Aires |
| Drug class | Benzodiazepine (alprazolam component); behavioral intervention (aerobic exercise component) |
| Target | GABA-A receptor (alprazolam); multiple neurobiological targets including monoamine systems and BDNF pathways (exercise) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Mental Health |
| Phase | FDA-approved |
Mechanism of action
Alprazolam is a benzodiazepine that potentiates GABA-A receptor signaling, increasing inhibitory neurotransmission and reducing neuronal excitability. Aerobic exercise complements this by promoting neuroplasticity, increasing brain-derived neurotrophic factor (BDNF), improving sleep quality, and enhancing cardiovascular efficiency—all of which contribute to anxiolytic and mood-stabilizing effects. The combination leverages both pharmacological and behavioral mechanisms to address anxiety disorders.
Approved indications
- Anxiety disorders with panic attacks
- Generalized anxiety disorder (GAD)
Common side effects
- Sedation / drowsiness
- Dizziness
- Dependence / withdrawal risk
- Cognitive impairment
- Muscle fatigue (exercise-related)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alprazolam + Aerobic exercise CI brief — competitive landscape report
- Alprazolam + Aerobic exercise updates RSS · CI watch RSS
- University of Buenos Aires portfolio CI